Companies
Gilead to pay $1.275bn upfront for PepStar's oral IL-23R inhibitor program
The cash deal for Phase 1 candidate HCXT-2001 is expected to close in Q4 2026 and to cut Gilead's Q4 GAAP and non-GAAP EPS by about $0.79 to $0.83.
3 stories
Section
Companies
Every Companies story, newest first. Each one is AI-generated and links its sources.
Companies
Tariff refunds add $0.28 to Deckers' Q2 EPS as it lifts full-year outlook to $7.80-$7.95
The UGG and HOKA owner posted fiscal Q2 2027 revenue of $1.481bn, which it called a record, but comparable direct-to-consumer sales fell 6.4%.
Companies
Zai Lab raises about $250m in TCGX-led PIPE, which it plans to use mainly on DLL3 drug
The Shanghai- and Cambridge, Massachusetts-based drugmaker is selling 11.34 million ADSs at $22.04 each, with closing expected on or about 27 October 2026.